Pre-made Benralizumab benchmark antibody ( Whole mAb, anti-IL5RA therapeutic antibody, Anti-CD125/CDw125/HSIL5R3/IL5R Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Benralizumab biosimilar, Whole mAb, Anti-IL5RA Antibody: Anti-CD125/CDw125/HSIL5R3/IL5R therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Benralizumab, sold under the brand name Fasenra, is a monoclonal antibody medication which is developed by MedImmune for the treatment of asthma. It is directed against the alpha-chain of the interleukin-5 receptor (CD125).[2][3]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-058-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Benralizumab biosimilar, Whole mAb, Anti-IL5RA Antibody: Anti-CD125/CDw125/HSIL5R3/IL5R therapeutic antibody
INN Name	Benralizumab
Target	IL5RA
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2009
Year Recommended	2010
Companies	AstraZeneca;Cincinnati Children's Hospital Medical Center;Kyowa Hakko;Kyowa Hakko Kirin;McMaster University;MedImmune;National Jewish Medical and Research Center;BioWa
Conditions Approved	Asthma
Conditions Active	Chronic obstructive pulmonary disease;Nasal polyps;Atopic dermatitis;Churg-Strauss syndrome;Hypereosinophilic syndrome;Rhinosinusitis;Eosinophilic gastroenteritis
Conditions Discontinued	Skin disorders
Development Tech	POTELLIGENT Technology